JSPR
MaterialsJasper Therapeutics Inc
$0.95-0.02 (-2.02%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving JSPR Today?
No stock-specific AI insight has been generated for JSPR yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$27M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume275K
Avg Volume (10D)—
Shares Outstanding28.0M
JSPR News
20 articles- Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7Yahoo Finance·Apr 7, 2026
- Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 30, 2026
- Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in BriquilimabYahoo Finance·Mar 29, 2026
- Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceYahoo Finance·Feb 24, 2026
- Jasper Therapeutics reports updated data from briquilimab studiesYahoo Finance·Jan 9, 2026
- Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous UrticariaYahoo Finance·Jan 8, 2026
- Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical GrowthYahoo Finance·Jan 7, 2026
- Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal InvestigationYahoo Finance·Dec 2, 2025
- Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study InvestigationYahoo Finance·Dec 1, 2025
- Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite RiskyYahoo Finance·Nov 20, 2025
- Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 10, 2025
- Jasper Therapeutics to Present at Upcoming Investor ConferencesYahoo Finance·Nov 4, 2025
- Positive Signs As Multiple Insiders Buy Jasper Therapeutics StockYahoo Finance·Oct 10, 2025
- Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common WarrantsYahoo Finance·Sep 18, 2025
- Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 13, 2025
- Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayYahoo Finance·Jul 9, 2025
- Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-BellYahoo Finance·Jul 7, 2025
- Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous UrticariaYahoo Finance·Jul 7, 2025
- Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaYahoo Finance·Jun 14, 2025
- Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressYahoo Finance·Jun 3, 2025
All 20 articles loaded
Price Data
Open$1.01
Previous Close$0.97
Day High$1.03
Day Low$0.94
52 Week High—
52 Week Low—
Fundamentals
Market Cap$27M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume275K
Avg Volume (10D)—
Shares Outstanding28.0M
About Jasper Therapeutics Inc
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—